Helio Costa, Senior Medical Director, Therapeutics & Innovations at Natera, shared a post on Linkedin:
“At AACR2026, we’re showcasing how Natera is expanding beyond MRD—using AI to turn routine pathology slides into scalable genomic insight.
Featured in an oral presentation, our new deep learning model—trained on over 45,000 CRC patients—enables genomic profiling and recurrence risk prediction directly from standard H&E images.
The impact:
- Predictive power: Detecting risk and hundreds of genomic alterations from a single slide
- Speed: Faster path from biopsy to actionable clinical insight
- Access: Expanding molecular data while reducing tissue constraints
By virtually profiling tumors, we’re addressing one of oncology’s biggest challenges: limited tissue. This work highlights the potential of AI-driven pathology to meaningfully shift the standard of care.
Huge kudos to our AI team on this milestone!
Read more in the press release.”